Product news from the 04/21/06 News Brief

Share this content:
The FDA has granted Fast Track designation to Schering-Plough’s investigational oral thrombin receptor antagonist (SCH 530348), currently in Phase II clinical development for secondary prevention of cardiovascular morbidity and mortality outcomes in at-risk patients.
Share this content:
Scroll down to see the next article